Posterior Uveitis Pharmaceutical and Healthcare Pipeline Review H2 adds “ Posterior Uveitis - Pipeline Review, H2 2016 ”reports to its database.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. One of the types of uveitis is posterior uveitis. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Get Sample Report @

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Posterior Uveitis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Posterior Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Posterior Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 3 respectively.Posterior Uveitis.

Posterior Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

- The pipeline guide provides a snapshot of the global therapeutic landscape of Posterior Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Posterior Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Posterior Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Posterior Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Posterior Uveitis (Ophthalmology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Posterior Uveitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Posterior Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Posterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Posterior Uveitis - Overview 7
Posterior Uveitis - Therapeutics under Development by Companies 8
Posterior Uveitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Posterior Uveitis - Products under Development by Companies 12
Posterior Uveitis - Companies Involved in Therapeutics Development 13
Aciont Inc. 13
Neuroptis Biotech 14
Oculis ehf 15
pSivida Corp. 16
Regeneron Pharmaceuticals Inc 17
Sandoz International GmbH 18
Santen Pharmaceutical Co., Ltd. 19
Posterior Uveitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
adalimumab biosimilar - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
dexamethasone acetate - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
dexamethasone sodium phosphate - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
EYS-606 - Drug Profile 33

Access Report @

Get in touch:

Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349

Release ID: 146307